# OnCo record anetumab-vs-vinorelbine-mpm (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/anetumab-vs-vinorelbine-mpm/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "anetumab-vs-vinorelbine-mpm", "NCT02610140" ;
  schema:name "Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma"@en ;
  schema:description "The first randomised test of an antibody-drug conjugate in mesothelioma: no better than vinorelbine, which is why no ADC is approved for this cancer."@en ;
  schema:url <https://onco.cc/trials/anetumab-vs-vinorelbine-mpm/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(22)00061-4>, <https://clinicaltrials.gov/study/NCT02610140> ;
  onco:status "negative" ;
  onco:tag "owner-request" ;
  onco:phase "2" ;
  schema:startDate "2015-12-03" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/mesothelin/> ;
  onco:drugs <https://onco.cc/drugs/anetumab-ravtansine/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kindler-lancet-oncol/> .